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Summary
Introduction: Varicella zoster (chickenpox) infection is a common and benign disease
of childhood. The predominance of uncomplicated cases in children tends to over-
shadow the morbidity associated with severe cases and the resultant hospitalization.
Objective: The objective was to establish the complication rate of chickenpox in the
Saudi National Guard population over a 2-year period.
Methods: All reported cases of chickenpox at the King Abdulaziz Medical City, Riyadh
were prospectively followed for development of complications during the period
between 1 June 2001 and 30 December 2003.
Results: A total of 3802 cases of chickenpox were reported and followed during the
acute illness phase. The majority of cases, 2984 (78%), occurred in children less than
15 years of age. Among all chickenpox cases, 78 (2%) required hospitalization, and 50
patients developed 58 (1.5%) complications. Skin and soft tissue infections were the
most common complications, 20 (34%), followed by pneumonia in 16 (28%), bacter-
emia in six (10%), encephalitis in four (7%) and necrotizing fasciitis in four (7%).
Complications were less common in children (36/2984, 1.2%) as compared to adults
(14/818, 1.7%) ( p = 0.26). However, pneumonia ( p = 0.03) and hospitalization
( p = 0.004) were more common in adults as compared to children. The overall fatality
rate was 0.05%; two patients died, one aged two months the other 28 years.* Corresponding author. Tel.: +966 01 2520088x3718; fax: +966 01 2520437.
E-mail address: memish@ngha.med.sa (Z.A. Memish).
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Varicella zoster (chickenpox) infection is an acute
common disease caused by the varicella zoster virus
(VZV).1—3 The disease can be benign and self-limit-
ing in children, but in adults and immunocompro-
mised hosts, it can be severe with high morbidity
and mortality.4—6
The epidemiology of chickenpox in Saudi Arabia is
unique in many ways. Firstly, chickenpox is a com-
mon disease and reported cases have increased in
the last three years.7 In the Ministry of Health (MOH)
Reportable Diseases Report, therewere 70 884 cases
of chickenpox reported for the year 2003, with an
overall prevalence of 322 cases/100 000 population,
a 33% increase over year 2002 (Figure 1).7 At the
National Guard Healthcare facilities, we noted the
same trend in the last three years, with total cases
of 1480, 2521, 4587 for years 2001, 2002, 2003,
respectively (Figure 1). Secondly, previous reports
within Saudi Arabia demonstrate that 16—25% of
chickenpox occurs in adults, and 15—20% of adults
are seronegative.8—10 This represents a high sus-
ceptibility and infection rate among adults, and
subsequently higher morbidity and mortality asso-
ciated with chickenpox.5 Thirdly, although chicken-
pox is often a benign and self-limiting childhood
illness, the disease can be associated with a variety
of serious and potentially fatal complications inFigure 1 The prevalence of cboth immunocompetent and immunocompromised
patients.11—14
There have been questions about the complica-
tions of chickenpox in Saudi Arabia, in comparison to
cases reported from developed countries,15 yet
there are no studies that have examined the rate
and severity of these complications among healthy
individuals in Saudi Arabia. Lastly, in Saudi Arabia
the live attenuated vaccine for varicella is not
incorporated into the recommended routine child-
hood immunization program. Based on this, the aim
of this study is to describe the epidemiology of
chickenpox complications, the major goal being to
promote universal varicella vaccination in Saudi
Arabia.Materials and methods
Setting
The study was conducted at King Abdulaziz Medical
City, Riyadh, King Fahad National Guard Hospital
(KFNGH). This is a 750-bed tertiary care center,
with eight satellite outpatient clinics. These clinics
serve the hospital, the housing compounds and the
military academies, and are located in different
areas in Riyadh, and are linked to KFNGH with the
same medical records and computer system. TheConclusion: These data provide a baseline for morbidity and mortality from chick-
enpox, and further support the inclusion of varicella vaccine in the routine childhood
immunization program in Saudi Arabia.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.hickenpox in Saudi Arabia.
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cers, employees and their dependents is approxi-
mately 100 000 people. Chickenpox is a reportable
disease in Saudi Arabia. All persons diagnosed with
chickenpox at any National Guard Health facilities,
are reported to the Infection Prevention and Control
Department for further reporting to the MOH.
Surveillance
Surveillance of chickenpox cases was started in June
2001, and continued over 30 months until December
2003. All reported cases were prospectively fol-
lowed for any complication or hospitalization.
Non-hospitalized patients were contacted by tel-
ephone during the first two weeks of illness and
medical records of hospitalized patients reviewed
for data collection.
Data collected included age, sex, date of clinic or
hospital visit, underlying disease(s), hospitalization,
and any complications. Multiple entries of compli-
cations for each patient were allowed.
Statistical analysis
Data collectedwere analyzed using Epi-Info software
(version 6.4, Center for Disease Control and Preven-
tion, Atlanta,GA). Pearson’s chi-square testwas used
to evaluate the relationship between independent
variables and complications. A p value of less than
0.05 was considered statistically significant.Results
During the period of 1 June 2001 to 30 December
2003, therewere 4121 cases of chickenpox reportedFigure 2 The incidence of chickenpox among the Nationalfrom the National Guard Healthcare facilities in the
Riyadh area. Of these, 3802 (92%) were followed
during their acute illness. There was a slight male
predominance with 1977 (52%) males and 1825
(48%) females. The majority of chickenpox cases,
2984 (78%) occurred in children less than 15 years of
age. Seventy-seven (2%) occurred in infants less
than one year of age, 644 (17%) in young children
aged 1—4 years, and 2263 (60%) in school-aged
children 5—14 years of age. Adults represented
818 (22%) of all cases; 768 (20%) were reported in
patients between 15 and 44 years of age and 50 (1%)
occurred in patients aged 45 years or above.
Although chickenpox occurred throughout the year,
there were seasonal peaks during the months of
March to June for the consecutive years 2002 and
2003 (Figure 2).
Seventy-eight (2%) patients with chickenpox
required hospitalization, 39 of these (50%) were
directly related to complications and 39 (50%) were
either for observation and/or initiation of intrave-
nous acyclovir. The overall hospitalization rate was
205/10 000 reported cases. Of all hospitalized cases
27 (35%) were adults with a rate of 330/10 000, and
51 (65%) were children with a rate of 170/10 000
(p < 0.004).
There were 58 (1.5%) complications in 50 patients
with an overall rate of 130 patients with complica-
tion/10 000 reported cases. Of these 50 patients, 39
(78%) required hospitalization and 11 (22%) were
treated as outpatients. The most common compli-
cations were skin and soft tissue infections which
accounted for 20 of the 58 (34%), followed by pneu-
monia which accounted for 16 (28%), bacteremia
for six (10%), encephalitis and cerebellitis for four
(7%), myositis and necrotizing fasciitis for four
(7%), and neonatal varicella for two (3%). OtherGuard population in each month during the study period.
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Table 1 The outcomes for 3802 patients with chick-
enpox during the period 1 June 2001 to 30 December
2003.
Variable N %
Total number of complications 58 1.5
Skin and soft tissue infections 20 34
Pneumonia 16 28
Bacteremia 6 10
Encephalitis/cerebellitis 4 7
Necrotizing fasciitis 4 7
Neonatal varicella 2 3
Other 6 10
Hospitalization 78 2
Mortality 2 0.05complications, septic shock (1), pyogenic arthritis
(2), hepatitis (1), endometritis and abortion (1), and
Guillian—Barre syndrome (1), made up the other 10%
(Table 1).
Group A beta hemolytic Streptococcus was the
cause of the bacteremia encountered in three of the
patients (50%), followed by Gram-negative bacilli
(Escherichia coli and Klebsiella pneumoniae) in two
(33%), and Enterococcus fecalis in one (17%). Com-
plications were more frequent in adults (14/818,
1.7%) compared to children (36/2984, 1.2%) but this
differencewas not statistically significant (p = 0.26).
However, pneumonia (p = 0.03) and hospitalization
(p = 0.004) occurred significantly more in adults
compared to children (Table 2).
All patients who developed complications were
healthy with no major underlying diseases except
for three (6%); one child with neuroblastoma on
chemotherapy, one with nephrotic syndrome on high
dose steroids and one adult with diabetes mellitus.
The overall mortality was two (0.05%) with a calcu-
lated rate of 5.3/10 000: one adult patient died of
pneumonia, and one child with Group A beta hemo-
lytic Streptococcus septic shock.Table 2 Comparison between the complications found am
Children (2984)
N %
Patients with complications 36 1.2
Skin infection/cellulitis 16 0.5
Pneumonia 9 0.3
Bacteremia 5 0.2
Encephalitis 2 0.0
Necrotizing fasciitis 4 0.1
Neonatal varicella 2 0.0
Others 3 0.1
Hospitalization 51 1.7
Mortality 1 0.0Discussion
The aim of the study was to quantify the complica-
tions of chickenpox in Saudi Arabia. By looking at all
reported cases of chickenpox and prospectively fol-
lowing them, we were able to obtain a complete and
accurate picture of the major complications. These
results indicate that the complication (130/10 000)
and hospitalization (205/10 000) rates of chickenpox
in our population are higher than those reported from
other countries; nevertheless the types of complica-
tions are very similar. 6,11,16—20 The complication rate
amongdifferent reports varies, dependingon theway
the data were collected and the type of complica-
tions included.16—18,21 In an epidemiological study in
the United States, prior to the initiation of varicella
vaccination, Choo et al. reported an overall hospita-
lization rate of 61/10 000 cases.17 In Canada, Rivest
et al. reported a complication rate in the province of
Quebec to be 92.2/10 000 cases.11 We believe that
the reasons for our high complication and hospitali-
zation rates couldbeattributed to thehighnumberof
affected adults, which accounted for 22% of all cases
of chickenpox in our population; in developed coun-
tries with temperate climates, adults represent only
3—5%of all cases.22 It iswell known that adults carry a
higher morbidity and mortality rate than children.5
Also, we reported all types of minor and major
complications that developed during the acute ill-
ness; other studies reported only complications that
required hospitalization.11,16,18,21 Furthermore, the
reporting system in Saudi Arabia is voluntary and only
cases that seek medical attention are reported, and
even this is dependent on the compliance of the
physician. This may reflect an incomplete record of
mild cases, which did not come tomedical attention.
Our mortality rate of 5.3/10 000 or 1 in 1900 is
considerably higher than rates of 1 in 29 000 in
England and Wales,23 1 in 33 000 in Canada,24 and
1 in 30—50 000 in the Unites States.25,26 We estimateong adults and children with chickenpox.
Adults (818) p Value
N %
14 1.7 0.26
4 0.5 0.87
7 0.9 0.03
1 0.1 0.77
7 2 0.2 0.17
0 0.0 —
7 0 0.0 —
3 0.4 0.09
27 3.3 0.004
3 1 0.1 0.32
160 M. Almuneef et al.that by applying our mortality andmorbidity rates on
the national level where 70 884 cases of chickenpox
were reported for the year 2003, there will be
approximately 1973 hospitalizations, 1467 complica-
tions, and 50 deaths from chickenpox each year in
Saudi Arabia.
Skin and soft tissue infections were the most
common complications of chickenpox and
accounted for 30—40% of all cases.11,17,18 One com-
plication that appears to be increasing in frequency
in the United States and Canada is serious bacterial
infection caused by Group A beta hemolytic strep-
tococci.27 Similarly, in this study, we found skin and
soft tissue infections to be the foremost complica-
tion accounting for 34%. Group A beta hemolytic
streptococci accounted for half the causes of sec-
ondary bacteremia, 7% necrotizing fasciitis, as well
as the cases of streptococcal toxic shock syndrome
and this is reflected in other such studies.17,18 Phy-
sicians in Saudi Arabia should be alerted to the
frequency of complications, and the recognition
of Group A beta hemolytic streptococcal infections
in patients with chickenpox. Pneumonia was the
second most common complication in our report,
and was found in 16 patients (28%). This is slightly
higher than previously reported,5,18 because 22% of
our chickenpox cases were adults, and it is well
known that pneumonia is a more common complica-
tion in adults than in children.
Although the types of complications are similar in
developed and developing countries,16—18,21 there is
little information from developing countries on the
disease burden and the impact of its complica-
tions.19,20 We believe that the disease burden, eco-
nomically and socially, would be similar or even
higher in Saudi Arabia in view of the fact that the
rate of complication and hospitalization is substan-
tially higher. Thus, from a public health point of
view, varicella and varicella complications could
prove to be more important in Saudi Arabia than
previously assumed, and widespread use of varicella
vaccination is highly recommended. The World
Health Organization (WHO) does not recommend
the inclusion of varicella vaccination in the routine
immunization programs of developing countries,27
the reason being that other vaccines such as hepa-
titis B and Haemophilus influenzae type B conjugate
vaccine should be given priority because of their
greater public health impact.28 In Saudi Arabia,
these vaccines are already included in the routine
childhood immunization program in addition to
diphtheria, pertussis, tetanus, polio, measles,
mumps, rubella, and bacille Calmette-Guerin
(BCG) vaccines. These vaccines have had a major
impact on diseases, lowering the incidence of some
and eradicating others.The recently marketed varicella vaccines are
shown to be safe and effective29—33 andwere recom-
mended by the American Academy of Pediatrics
(AAP) and the Advisory Committee on Immunization
Practices (ACIP) for routine childhood immuniza-
tion.34,35 From a societal perspective, a recent
cost—benefit analysis showed that routine chicken-
pox vaccination is likely to save five times the
investment for a National Immunization Pro-
gram.36,37 Similar studies from developing countries
are not available. In view of the fact that the types
of complications are similar to those reported in
developed countries, and that the frequency of
complication and rate of hospitalization are higher,
the socioeconomic benefits of varicella vaccination
are likely to be the same or even higher in countries
like Saudi Arabia.
In conclusion, complications and hospitalization
secondary to chickenpox are very common in Saudi
Arabia. Thus, from the public health point of view,
varicella vaccine could prove to be more important
in Saudi Arabia than previously assumed.
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